person · Reporting owner

Canute Scott A

Disclosed activity across 7 companies

Tapewire entity: 13586
SEC CIK: 0001303416

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Akebia Therapeutics, Inc.AKBA · Entity 6105	Director	June 06, 2019	June 10, 2019
ELI LILLY & CoLLY · Entity 2794	President, Mfg. Operations	December 31, 2006	February 12, 2007
Oncorus, Inc.ONCR · Entity 112213	Director	June 23, 2022	June 24, 2022
Outlook Therapeutics, Inc.ONS · Entity 608	Director	October 26, 2017	October 30, 2017
Protara Therapeutics, Inc.PRTO · Entity 6203	Director	June 08, 2018	June 11, 2018

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Akebia Therapeutics, Inc.

Report date June 06, 2019 · Filed June 10, 2019

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	13,700	Reported balance After 2019-06-06 transaction · row 1 1 source row Row 1 · 2019-06-06 · Grant · Acquired 13,700 · Balance 13,700 F1: The restricted stock units were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended, as provided by the Issuer's Amended and Restated Non-Employee Director Compensation Program (the "RSUs"). 100% of the RSUs will vest on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer.
Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.23 · Expires 2029-06-06	Direct	20,100	Reported balance After 2019-06-06 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2019-06-06 · Grant · Acquired 20,100 · Balance 20,100 F2: Represents an option to purchase shares of the Issuer's common stock granted by the Issuer pursuant to its 2014 Incentive Plan, as amended, as provided by the Issuer's Amended and Restated Non-Employee Director Compensation Program (the "Stock Option"). 100% of the Stock Option will vest and become exercisable on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer.

Filing footnotes · ownership attribution and instrument terms

F1: The restricted stock units were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended, as provided by the Issuer's Amended and Restated Non-Employee Director Compensation Program (the "RSUs"). 100% of the RSUs will vest on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer.

F2: Represents an option to purchase shares of the Issuer's common stock granted by the Issuer pursuant to its 2014 Incentive Plan, as amended, as provided by the Issuer's Amended and Restated Non-Employee Director Compensation Program (the "Stock Option"). 100% of the Stock Option will vest and become exercisable on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer.

ELI LILLY & Co

Report date December 31, 2006 · Filed February 12, 2007

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectAmy D. Canute Rev. Trust	18,078	Reported balance After 2006-06-13 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2006-06-13 · Gift · Disposed 1,293 · Balance 18,078 F1: Revocable Trust of which reporting person and his wife are trustee.
Common StockSEC Table I · non-derivative	Direct	11,680	Reported balance Holding disclosure · report date 2006-12-31 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 11,680
Common StockSEC Table I · non-derivative	Indirect401(k)	5,935	Reported balance Holding disclosure · report date 2006-12-31 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 5,935

Filing footnotes · ownership attribution and instrument terms

F1: Revocable Trust of which reporting person and his wife are trustee.

Oncorus, Inc.

Report date June 23, 2022 · Filed June 24, 2022

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.60 · Expires 2032-06-23	Direct	12,500	Reported balance After 2022-06-23 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2022-06-23 · Grant · Acquired 12,500 · Balance 12,500 F1: The option shall vest in twelve (12) equal monthly installments commencing on July 23, 2022, subject to the Reporting Person continuing to provide service through each such date.

Filing footnotes · ownership attribution and instrument terms

F1: The option shall vest in twelve (12) equal monthly installments commencing on July 23, 2022, subject to the Reporting Person continuing to provide service through each such date.

Outlook Therapeutics, Inc.

Report date October 26, 2017 · Filed October 30, 2017

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.32 · Expires 2027-10-26	Direct	15,000	Reported balance After 2017-10-26 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2017-10-26 · Grant · Acquired 15,000 · Balance 15,000 F1: 100% of the shares underlying the option shall vest on October 26, 2018, subject to the Reporting Person providing continuous service to the Issuer on such date.

Filing footnotes · ownership attribution and instrument terms

F1: 100% of the shares underlying the option shall vest on October 26, 2018, subject to the Reporting Person providing continuous service to the Issuer on such date.

Protara Therapeutics, Inc.

Report date June 08, 2018 · Filed June 11, 2018

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.50 · Expires 2028-06-07	Direct	12,700	Reported balance After 2018-06-08 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2018-06-08 · Grant · Acquired 12,700 · Balance 12,700 F1: The options were granted on June 8, 2018 and the shares underlying this option will vest 100% at the earlier of (i) June 8, 2019 and (ii) the Issuer's next annual meeting of stockholders.

Filing footnotes · ownership attribution and instrument terms

F1: The options were granted on June 8, 2018 and the shares underlying this option will vest 100% at the earlier of (i) June 8, 2019 and (ii) the Issuer's next annual meeting of stockholders.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Flexion Therapeutics Inc

Report date November 19, 2021 · Filed November 19, 2021

Section 16 reporting ended · disclosed 2021-11-19. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2021-11-19 transaction · row 1 1 source row Row 1 · 2021-11-19 · Disposition to issuer · Disposed 9,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2021, by and among Flexion Therapeutics, Inc. ("Issuer"), Pacira BioSciences, Inc. and Oyster Acquisition Company Inc. ("Purchaser") ("Merger Agreement"), on November 19, 2021, Purchaser merged with and into Issuer, with Issuer continuing as the surviving corporation ("Merger"). At the effective time of the Merger, each share of Issuer's common stock was cancelled in exchange for (i) $8.50 per share in cash ("Cash Amount"), plus (ii) one non-transferable contractual contingent value right per share, which represent the right to receive one or more contingent payments of up to $8.00 per share in the aggregate, in cash, upon the achievement of specified milestones on or prior to December 31, 2030 ("CVR Payments"). Pursuant to the Merger Agreement, these shares were tendered and disposed of at the offer acceptance time in exchange for the right to receive (i) the Cash Amount, plus (ii) any CVR Payments. F2: At the effective time of the Merger, each outstanding restricted stock unit award ("RSU") was accelerated and became fully vested and was cancelled and converted into the right to receive (i) $8.50 per share of Issuer common stock issuable in settlement of such RSU in cash, net of any withholding taxes required to be deducted and withheld by applicable law, plus (ii) any potential CVR Payments.
Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $25.38 · Expires 2025-03-03	Direct	Reported balance After 2021-11-19 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2021-11-19 · Disposition to issuer · Disposed 18,000 · Balance 0 F3: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option.
Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.85 · Expires 2025-06-16	Direct	Reported balance After 2021-11-19 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2021-11-19 · Disposition to issuer · Disposed 9,000 · Balance 0 F3: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option.
Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.83 · Expires 2026-06-09	Direct	Reported balance After 2021-11-19 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2021-11-19 · Disposition to issuer · Disposed 12,500 · Balance 0 F3: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option.
Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.16 · Expires 2027-06-21	Direct	Reported balance After 2021-11-19 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2021-11-19 · Disposition to issuer · Disposed 12,500 · Balance 0 F3: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option.
Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.14 · Expires 2028-06-19	Direct	Reported balance After 2021-11-19 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2021-11-19 · Disposition to issuer · Disposed 12,500 · Balance 0 F3: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option.
Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.74 · Expires 2029-06-18	Direct	Reported balance After 2021-11-19 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2021-11-19 · Disposition to issuer · Disposed 12,500 · Balance 0 F3: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option.
Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.88 · Expires 2030-06-09	Direct	Reported balance After 2021-11-19 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2021-11-19 · Disposition to issuer · Disposed 7,000 · Balance 0 F3: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option.
Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.22 · Expires 2031-06-23	Direct	Reported balance After 2021-11-19 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2021-11-19 · Disposition to issuer · Disposed 7,000 · Balance 0 F3: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2021, by and among Flexion Therapeutics, Inc. ("Issuer"), Pacira BioSciences, Inc. and Oyster Acquisition Company Inc. ("Purchaser") ("Merger Agreement"), on November 19, 2021, Purchaser merged with and into Issuer, with Issuer continuing as the surviving corporation ("Merger"). At the effective time of the Merger, each share of Issuer's common stock was cancelled in exchange for (i) $8.50 per share in cash ("Cash Amount"), plus (ii) one non-transferable contractual contingent value right per share, which represent the right to receive one or more contingent payments of up to $8.00 per share in the aggregate, in cash, upon the achievement of specified milestones on or prior to December 31, 2030 ("CVR Payments"). Pursuant to the Merger Agreement, these shares were tendered and disposed of at the offer acceptance time in exchange for the right to receive (i) the Cash Amount, plus (ii) any CVR Payments.

F2: At the effective time of the Merger, each outstanding restricted stock unit award ("RSU") was accelerated and became fully vested and was cancelled and converted into the right to receive (i) $8.50 per share of Issuer common stock issuable in settlement of such RSU in cash, net of any withholding taxes required to be deducted and withheld by applicable law, plus (ii) any potential CVR Payments.

F3: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option.

IMMUNOMEDICS INC

Report date October 23, 2020 · Filed October 23, 2020

Section 16 reporting ended · disclosed 2020-10-23. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2020-10-23 transaction · row 1 1 source row Row 1 · 2020-10-23 · Disposition to issuer · Disposed 13,516 · Balance 0 F1: In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.01 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was automatically cancelled and converted into the right to receive $88.00 in cash (the "Offer Price"), without interest and subject to required withholding taxes.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security	Direct	Reported balance After 2020-10-23 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2020-10-23 · Disposition to issuer · Disposed 155,286 · Balance 0 F2: In connection with the consummation of the Merger, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") that was outstanding as of immediately prior to the Effective Time, whether vested or not vested, was automatically cancelled and converted into the right to receive an amount in cash equal to (i) the excess, if any, of the Offer Price over the exercise price payable per share subject to such Stock Option, multiplied by (ii) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time. Any Stock Option that had an exercise price per share that was equal to or greater than the Offer Price was cancelled for no consideration.
Restricted Stock UnitSEC Table II · derivative / convertible security	Direct	Reported balance After 2020-10-23 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2020-10-23 · Disposition to issuer · Disposed 3,718 · Balance 0 F3: In connection with the consummation of the Merger, at the Effective Time, each restricted stock unit to acquire shares of Common Stock ("Restricted Stock Unit") that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash equal to (A) the Offer Price, multiplied by (B) the total number of shares of Common Stock subject to such Restricted Stock Unit immediately prior to the Effective Time.

Filing footnotes · ownership attribution and instrument terms

F1: In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.01 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was automatically cancelled and converted into the right to receive $88.00 in cash (the "Offer Price"), without interest and subject to required withholding taxes.

F2: In connection with the consummation of the Merger, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") that was outstanding as of immediately prior to the Effective Time, whether vested or not vested, was automatically cancelled and converted into the right to receive an amount in cash equal to (i) the excess, if any, of the Offer Price over the exercise price payable per share subject to such Stock Option, multiplied by (ii) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time. Any Stock Option that had an exercise price per share that was equal to or greater than the Offer Price was cancelled for no consideration.

F3: In connection with the consummation of the Merger, at the Effective Time, each restricted stock unit to acquire shares of Common Stock ("Restricted Stock Unit") that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash equal to (A) the Offer Price, multiplied by (B) the total number of shares of Common Stock subject to such Restricted Stock Unit immediately prior to the Effective Time.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 23, 2022 Filed Jun 24, 2022 06:39 UTC	Oncorus, Inc. ONCR · Entity 112213	GrantStock Option (right to buy) · Derivative	12,500	$0.00 Strike: $1.60	$0.00	Disclosure SEC source: 0001209191-22-039082 · doc4.xml · derivative · entry 1 Canute Scott A · CIK 0001303416 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2032-06-23 F1 · derivative.exercise_date: The option shall vest in twelve (12) equal monthly installments commencing on July 23, 2022, subject to the Reporting Person continuing to provide service through each such date. Read SEC document
November 19, 2021 Filed Nov 19, 2021 10:10 UTC	Flexion Therapeutics Inc FLXN · Entity 16545	Disposition to issuerStock option (right to buy) · Derivative	7,000	Not disclosed Strike: $9.22	Not disclosed	Disclosure SEC source: 0001209191-21-065715 · doc4.xml · derivative · entry 9 Canute Scott A · CIK 0001303416 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,000 shares Expires 2031-06-23 F3 · price: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. F3 · derivative.exercise_date: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. Read SEC document
November 19, 2021 Filed Nov 19, 2021 10:10 UTC	Flexion Therapeutics Inc FLXN · Entity 16545	Disposition to issuerStock option (right to buy) · Derivative	7,000	Not disclosed Strike: $11.88	Not disclosed	Disclosure SEC source: 0001209191-21-065715 · doc4.xml · derivative · entry 8 Canute Scott A · CIK 0001303416 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,000 shares Expires 2030-06-09 F3 · price: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. F3 · derivative.exercise_date: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. Read SEC document
November 19, 2021 Filed Nov 19, 2021 10:10 UTC	Flexion Therapeutics Inc FLXN · Entity 16545	Disposition to issuerStock option (right to buy) · Derivative	12,500	Not disclosed Strike: $11.74	Not disclosed	Disclosure SEC source: 0001209191-21-065715 · doc4.xml · derivative · entry 7 Canute Scott A · CIK 0001303416 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,500 shares Expires 2029-06-18 F3 · price: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. F3 · derivative.exercise_date: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. Read SEC document
November 19, 2021 Filed Nov 19, 2021 10:10 UTC	Flexion Therapeutics Inc FLXN · Entity 16545	Disposition to issuerStock option (right to buy) · Derivative	12,500	Not disclosed Strike: $28.14	Not disclosed	Disclosure SEC source: 0001209191-21-065715 · doc4.xml · derivative · entry 6 Canute Scott A · CIK 0001303416 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,500 shares Expires 2028-06-19 F3 · price: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. F3 · derivative.exercise_date: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. Read SEC document
November 19, 2021 Filed Nov 19, 2021 10:10 UTC	Flexion Therapeutics Inc FLXN · Entity 16545	Disposition to issuerStock option (right to buy) · Derivative	12,500	Not disclosed Strike: $20.16	Not disclosed	Disclosure SEC source: 0001209191-21-065715 · doc4.xml · derivative · entry 5 Canute Scott A · CIK 0001303416 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,500 shares Expires 2027-06-21 F3 · price: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. F3 · derivative.exercise_date: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. Read SEC document
November 19, 2021 Filed Nov 19, 2021 10:10 UTC	Flexion Therapeutics Inc FLXN · Entity 16545	Disposition to issuerStock option (right to buy) · Derivative	12,500	Not disclosed Strike: $13.83	Not disclosed	Disclosure SEC source: 0001209191-21-065715 · doc4.xml · derivative · entry 4 Canute Scott A · CIK 0001303416 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,500 shares Expires 2026-06-09 F3 · price: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. F3 · derivative.exercise_date: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. Read SEC document
November 19, 2021 Filed Nov 19, 2021 10:10 UTC	Flexion Therapeutics Inc FLXN · Entity 16545	Disposition to issuerStock option (right to buy) · Derivative	9,000	Not disclosed Strike: $21.85	Not disclosed	Disclosure SEC source: 0001209191-21-065715 · doc4.xml · derivative · entry 3 Canute Scott A · CIK 0001303416 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,000 shares Expires 2025-06-16 F3 · price: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. F3 · derivative.exercise_date: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. Read SEC document
November 19, 2021 Filed Nov 19, 2021 10:10 UTC	Flexion Therapeutics Inc FLXN · Entity 16545	Disposition to issuerStock option (right to buy) · Derivative	18,000	Not disclosed Strike: $25.38	Not disclosed	Disclosure SEC source: 0001209191-21-065715 · doc4.xml · derivative · entry 2 Canute Scott A · CIK 0001303416 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,000 shares Expires 2025-03-03 F3 · price: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. F3 · derivative.exercise_date: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. Read SEC document
November 19, 2021 Filed Nov 19, 2021 10:10 UTC	Flexion Therapeutics Inc FLXN · Entity 16545	Disposition to issuerCommon Stock	9,000	$8.50	$76,500.00	Disclosure SEC source: 0001209191-21-065715 · doc4.xml · nonDerivative · entry 1 Canute Scott A · CIK 0001303416 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2021, by and among Flexion Therapeutics, Inc. ("Issuer"), Pacira BioSciences, Inc. and Oyster Acquisition Company Inc. ("Purchaser") ("Merger Agreement"), on November 19, 2021, Purchaser merged with and into Issuer, with Issuer continuing as the surviving corporation ("Merger"). At the effective time of the Merger, each share of Issuer's common stock was cancelled in exchange for (i) $8.50 per share in cash ("Cash Amount"), plus (ii) one non-transferable contractual contingent value right per share, which represent the right to receive one or more contingent payments of up to $8.00 per share in the aggregate, in cash, upon the achievement of specified milestones on or prior to December 31, 2030 ("CVR Payments"). Pursuant to the Merger Agreement, these shares were tendered and disposed of at the offer acceptance time in exchange for the right to receive (i) the Cash Amount, plus (ii) any CVR Payments. F2 · shares: At the effective time of the Merger, each outstanding restricted stock unit award ("RSU") was accelerated and became fully vested and was cancelled and converted into the right to receive (i) $8.50 per share of Issuer common stock issuable in settlement of such RSU in cash, net of any withholding taxes required to be deducted and withheld by applicable law, plus (ii) any potential CVR Payments. Read SEC document
June 24, 2021 Filed Jun 28, 2021 18:38 UTC	Flexion Therapeutics Inc FLXN · Entity 16545	GrantStock option (right to buy) · Derivative	7,000	$0.00 Strike: $9.22	$0.00	Disclosure SEC source: 0001209191-21-043554 · doc4.xml · derivative · entry 2 Canute Scott A · CIK 0001303416 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,000 Underlying: Common Stock · 7,000 shares Expires 2031-06-23 F2 · derivative.exercise_date: The stock option vests and becomes exercisable in 12 equal monthly installments following the date of grant. Read SEC document
June 24, 2021 Filed Jun 28, 2021 18:38 UTC	Flexion Therapeutics Inc FLXN · Entity 16545	GrantCommon Stock	4,500	$0.00	$0.00	Disclosure SEC source: 0001209191-21-043554 · doc4.xml · nonDerivative · entry 1 Canute Scott A · CIK 0001303416 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 F1 · shares: Represents a restricted stock unit award granted under the Issuer's 2013 Equity Incentive Plan. Read SEC document
June 16, 2021 Filed Jun 17, 2021 17:54 UTC	Oncorus, Inc. ONCR · Entity 112213	GrantStock Option (right to buy) · Derivative	12,500	$0.00 Strike: $16.55	$0.00	Disclosure SEC source: 0001209191-21-041613 · doc4.xml · derivative · entry 1 Canute Scott A · CIK 0001303416 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2031-06-15 F1 · derivative.exercise_date: The option shall vest in 12 equal monthly installments commencing on July 16, 2021, subject to the Reporting Person continuing to provide service through each such date. Read SEC document
December 11, 2020 Filed Dec 16, 2020 17:15 UTC	Oncorus, Inc. ONCR · Entity 112213	GrantStock Option (right to buy) · Derivative	25,000	$0.00 Strike: $26.00	$0.00	Disclosure SEC source: 0001209191-20-063838 · doc4.xml · derivative · entry 1 Canute Scott A · CIK 0001303416 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2030-12-10 F1 · derivative.exercise_date: One-third of the shares subject to the option shall vest on December 11, 2021, and one twenty-fourth (1/24th) of the remaining shares subject to the option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date. Read SEC document
December 11, 2020 Filed Jun 17, 2021 17:45 UTC Amendment	Oncorus, Inc. ONCR · Entity 112213	GrantStock Option (right to buy) · Derivative	25,000	$0.00 Strike: $26.00	$0.00	Disclosure SEC source: 0001209191-21-041603 · doc4a.xml · derivative · entry 1 Canute Scott A · CIK 0001303416 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2030-12-10 F1 · derivative.exercise_date: The original Form 4 filed on December 16, 2020 inadvertently listed the incorrect vesting terms. The correct vesting is: one thirty-sixth (1/36th) of the shares subject to the option shall vest each month commencing on January 11, 2021, subject to the Reporting Person continuing to provide service through each such date. Read SEC document
October 23, 2020 Filed Oct 23, 2020 17:34 UTC	IMMUNOMEDICS INC IMMU · Entity 145732	Disposition to issuerRestricted Stock Unit · Derivative	3,718	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-20-117803 · a4.xml · derivative · entry 3 Canute Scott A · CIK 0001303416 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,718 shares Expires not disclosed F3 · derivative.exercise_price: In connection with the consummation of the Merger, at the Effective Time, each restricted stock unit to acquire shares of Common Stock ("Restricted Stock Unit") that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash equal to (A) the Offer Price, multiplied by (B) the total number of shares of Common Stock subject to such Restricted Stock Unit immediately prior to the Effective Time. F3 · price: In connection with the consummation of the Merger, at the Effective Time, each restricted stock unit to acquire shares of Common Stock ("Restricted Stock Unit") that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash equal to (A) the Offer Price, multiplied by (B) the total number of shares of Common Stock subject to such Restricted Stock Unit immediately prior to the Effective Time. F3 · derivative.exercise_date: In connection with the consummation of the Merger, at the Effective Time, each restricted stock unit to acquire shares of Common Stock ("Restricted Stock Unit") that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash equal to (A) the Offer Price, multiplied by (B) the total number of shares of Common Stock subject to such Restricted Stock Unit immediately prior to the Effective Time. F3 · derivative.expiration_date: In connection with the consummation of the Merger, at the Effective Time, each restricted stock unit to acquire shares of Common Stock ("Restricted Stock Unit") that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash equal to (A) the Offer Price, multiplied by (B) the total number of shares of Common Stock subject to such Restricted Stock Unit immediately prior to the Effective Time. Read SEC document
October 23, 2020 Filed Oct 23, 2020 17:34 UTC	IMMUNOMEDICS INC IMMU · Entity 145732	Disposition to issuerStock Option (Right to Buy) · Derivative	155,286	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-20-117803 · a4.xml · derivative · entry 2 Canute Scott A · CIK 0001303416 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 155,286 shares Expires not disclosed F2 · derivative.exercise_price: In connection with the consummation of the Merger, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") that was outstanding as of immediately prior to the Effective Time, whether vested or not vested, was automatically cancelled and converted into the right to receive an amount in cash equal to (i) the excess, if any, of the Offer Price over the exercise price payable per share subject to such Stock Option, multiplied by (ii) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time. Any Stock Option that had an exercise price per share that was equal to or greater than the Offer Price was cancelled for no consideration. F2 · price: In connection with the consummation of the Merger, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") that was outstanding as of immediately prior to the Effective Time, whether vested or not vested, was automatically cancelled and converted into the right to receive an amount in cash equal to (i) the excess, if any, of the Offer Price over the exercise price payable per share subject to such Stock Option, multiplied by (ii) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time. Any Stock Option that had an exercise price per share that was equal to or greater than the Offer Price was cancelled for no consideration. F2 · derivative.exercise_date: In connection with the consummation of the Merger, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") that was outstanding as of immediately prior to the Effective Time, whether vested or not vested, was automatically cancelled and converted into the right to receive an amount in cash equal to (i) the excess, if any, of the Offer Price over the exercise price payable per share subject to such Stock Option, multiplied by (ii) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time. Any Stock Option that had an exercise price per share that was equal to or greater than the Offer Price was cancelled for no consideration. F2 · derivative.expiration_date: In connection with the consummation of the Merger, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") that was outstanding as of immediately prior to the Effective Time, whether vested or not vested, was automatically cancelled and converted into the right to receive an amount in cash equal to (i) the excess, if any, of the Offer Price over the exercise price payable per share subject to such Stock Option, multiplied by (ii) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time. Any Stock Option that had an exercise price per share that was equal to or greater than the Offer Price was cancelled for no consideration. Read SEC document
October 23, 2020 Filed Oct 23, 2020 17:34 UTC	IMMUNOMEDICS INC IMMU · Entity 145732	Disposition to issuerCommon Stock	13,516	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-20-117803 · a4.xml · nonDerivative · entry 1 Canute Scott A · CIK 0001303416 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.01 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was automatically cancelled and converted into the right to receive $88.00 in cash (the "Offer Price"), without interest and subject to required withholding taxes. F1 · price: In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.01 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was automatically cancelled and converted into the right to receive $88.00 in cash (the "Offer Price"), without interest and subject to required withholding taxes. Read SEC document
June 18, 2020 Filed Jun 22, 2020 17:19 UTC	IMMUNOMEDICS INC IMMU · Entity 145732	GrantStock Option (right to buy) · Derivative	6,540	$0.00 Strike: $33.62	$0.00	Disclosure SEC source: 0001104659-20-075693 · a4.xml · derivative · entry 2 Canute Scott A · CIK 0001303416 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,540 Underlying: Common Stock, par value $0.01 per share · 6,540 shares Expires 2030-06-18 F1 · date: Such grants of restricted stock units and stock options were made automatically pursuant to the Issuer's compensation policy for non-employee directors as of the date of the Issuer's 2020 annual meeting of stockholders, which occurred on June 18, 2020. F3 · derivative.exercise_date: The stock options vest on the first anniversary of the date of grant, subject to the Reporting Person's continued service as a director of the Issuer. Read SEC document
June 18, 2020 Filed Jun 22, 2020 17:19 UTC	IMMUNOMEDICS INC IMMU · Entity 145732	GrantCommon Stock, $0.01 par value per share	3,718	$0.00	$0.00	Disclosure SEC source: 0001104659-20-075693 · a4.xml · nonDerivative · entry 1 Canute Scott A · CIK 0001303416 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,234 F1 · date: Such grants of restricted stock units and stock options were made automatically pursuant to the Issuer's compensation policy for non-employee directors as of the date of the Issuer's 2020 annual meeting of stockholders, which occurred on June 18, 2020. F2 · shares: Includes restricted stock units that represent a contingent right to receive one share of the Issuer's common stock. The restricted stock units shall vest on the first anniversary of the date of grant, subject to the Reporting Person's continued service as a director of the Issuer. Read SEC document
June 10, 2020 Filed Jun 12, 2020 16:11 UTC	Flexion Therapeutics Inc FLXN · Entity 16545	GrantStock option (right to buy) · Derivative	7,000	$0.00 Strike: $11.88	$0.00	Disclosure SEC source: 0001209191-20-036247 · doc4.xml · derivative · entry 2 Canute Scott A · CIK 0001303416 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,000 Underlying: Common Stock · 7,000 shares Expires 2030-06-09 F2 · derivative.exercise_date: The stock option vests and becomes exercisable in 12 equal monthly installments following the date of grant. Read SEC document
June 10, 2020 Filed Jun 12, 2020 16:11 UTC	Flexion Therapeutics Inc FLXN · Entity 16545	GrantCommon Stock	4,500	$0.00	$0.00	Disclosure SEC source: 0001209191-20-036247 · doc4.xml · nonDerivative · entry 1 Canute Scott A · CIK 0001303416 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,500 F1 · shares: Represents restricted stock unit award granted under the Issuer's 2013 Equity Incentive Plan. Read SEC document
June 19, 2019 Filed Jun 21, 2019 16:04 UTC	Flexion Therapeutics Inc FLXN · Entity 16545	GrantStock option (right to buy) · Derivative	12,500	$0.00 Strike: $11.74	$0.00	Disclosure SEC source: 0001209191-19-038454 · doc4.xml · derivative · entry 1 Canute Scott A · CIK 0001303416 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2029-06-18 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 12 equal monthly installments following the date of grant. Read SEC document
June 07, 2019 Filed Jun 11, 2019 16:29 UTC	IMMUNOMEDICS INC IMMU · Entity 145732	GrantStock Option (right to buy) · Derivative	17,077	$0.00 Strike: $12.93	$0.00	Disclosure SEC source: 0001104659-19-034787 · a4.xml · derivative · entry 2 Canute Scott A · CIK 0001303416 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,077 Underlying: Common Stock, par value $0.01 per share · 17,077 shares Expires 2026-06-07 F1 · date: Such grants of restricted stock units and stock options were made automatically pursuant to the Issuer's compensation policy for non-employee directors as of the date of the Issuer's 2019 annual meeting of stockholders, which occurred on June 7, 2019. F3 · derivative.exercise_date: The stock options vest on the first anniversary of the date of grant, subject to the Reporting Person's continued service as a director of the Issuer. Read SEC document
June 07, 2019 Filed Jun 11, 2019 16:29 UTC	IMMUNOMEDICS INC IMMU · Entity 145732	GrantCommon Stock, $0.01 par value per share	9,667	$0.00	$0.00	Disclosure SEC source: 0001104659-19-034787 · a4.xml · nonDerivative · entry 1 Canute Scott A · CIK 0001303416 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,516 F1 · date: Such grants of restricted stock units and stock options were made automatically pursuant to the Issuer's compensation policy for non-employee directors as of the date of the Issuer's 2019 annual meeting of stockholders, which occurred on June 7, 2019. F2 · shares: Includes restricted stock units that represent a contingent right to receive one share of the Issuer's common stock. The restricted stock units shall vest on the first anniversary of the date of grant, subject to the Reporting Person's continued service as a director of the Issuer. F2 · balance_after: Includes restricted stock units that represent a contingent right to receive one share of the Issuer's common stock. The restricted stock units shall vest on the first anniversary of the date of grant, subject to the Reporting Person's continued service as a director of the Issuer. Read SEC document
June 06, 2019 Filed Jun 10, 2019 16:03 UTC	Akebia Therapeutics, Inc. AKBA · Entity 6105	GrantStock Option (Right to buy) · Derivative	20,100	$0.00 Strike: $4.23	$0.00	Disclosure SEC source: 0001562180-19-003433 · primarydocument.xml · derivative · entry 2 Canute Scott A · CIK 0001303416 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,100 Underlying: Common Stock · 20,100 shares Expires 2029-06-06 F2 · shares: Represents an option to purchase shares of the Issuer's common stock granted by the Issuer pursuant to its 2014 Incentive Plan, as amended, as provided by the Issuer's Amended and Restated Non-Employee Director Compensation Program (the "Stock Option"). 100% of the Stock Option will vest and become exercisable on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer. Read SEC document
June 06, 2019 Filed Jun 10, 2019 16:03 UTC	Akebia Therapeutics, Inc. AKBA · Entity 6105	GrantCommon Stock	13,700	$0.00	$0.00	Disclosure SEC source: 0001562180-19-003433 · primarydocument.xml · nonDerivative · entry 1 Canute Scott A · CIK 0001303416 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,700 F1 · shares: The restricted stock units were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended, as provided by the Issuer's Amended and Restated Non-Employee Director Compensation Program (the "RSUs"). 100% of the RSUs will vest on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer. Read SEC document
March 08, 2019 Filed Mar 11, 2019 16:48 UTC	IMMUNOMEDICS INC IMMU · Entity 145732	GrantStock Option (right to buy) · Derivative	22,854	$0.00 Strike: $16.35	$0.00	Disclosure SEC source: 0001104659-19-013869 · a4.xml · derivative · entry 2 Canute Scott A · CIK 0001303416 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,854 Underlying: Common Stock, par value $0.01 per share · 22,854 shares Expires 2026-03-08 F1 · derivative.exercise_date: The reporting person was granted stock options pursuant to the Issuer's 2014 Long-Term Incentive Plan. The stock options vest in full upon the Issuer's receipt of approval from the U.S. Food and Drug Administration for the Issuer's Biologics License Application for sacituzumab govitecan for the treatment of patients with metastatic triple-negative breast cancer who have received at least two prior therapies for metastatic disease under the Prescription Drug User Fee Act. Read SEC document
March 05, 2019 Filed Mar 11, 2019 16:48 UTC	IMMUNOMEDICS INC IMMU · Entity 145732	GrantStock Option (right to buy) · Derivative	79,818	$0.00 Strike: $16.96	$0.00	Disclosure SEC source: 0001104659-19-013869 · a4.xml · derivative · entry 1 Canute Scott A · CIK 0001303416 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,818 Underlying: Common Stock, par value $0.01 per share · 79,818 shares Expires 2026-03-05 F1 · derivative.exercise_date: The reporting person was granted stock options pursuant to the Issuer's 2014 Long-Term Incentive Plan. The stock options vest in full upon the Issuer's receipt of approval from the U.S. Food and Drug Administration for the Issuer's Biologics License Application for sacituzumab govitecan for the treatment of patients with metastatic triple-negative breast cancer who have received at least two prior therapies for metastatic disease under the Prescription Drug User Fee Act. Read SEC document
June 20, 2018 Filed Jun 21, 2018 16:10 UTC	Flexion Therapeutics Inc FLXN · Entity 16545	GrantStock option (right to buy) · Derivative	12,500	$0.00 Strike: $28.14	$0.00	Disclosure SEC source: 0001209191-18-038931 · doc4.xml · derivative · entry 1 Canute Scott A · CIK 0001303416 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2028-06-19 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 12 equal monthly installments following the date of grant. Read SEC document
June 14, 2018 Filed Jun 15, 2018 08:16 UTC	Akebia Therapeutics, Inc. AKBA · Entity 6105	GrantStock Option (Right to buy) · Derivative	12,500	$0.00 Strike: $11.14	$0.00	Disclosure SEC source: 0001562180-18-003014 · primarydocument.xml · derivative · entry 1 Canute Scott A · CIK 0001303416 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2028-06-14 F1 · shares: Represents an option to purchase shares of Akebia Therapeutics, Inc.'s (the "Company's") common stock granted by the Company pursuant to the Company's 2014 Incentive Plan (the "Stock Option"). 100% of the Stock Option will vest and become exercisable on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Company. Read SEC document
June 08, 2018 Filed Jun 11, 2018 16:31 UTC	Protara Therapeutics, Inc. PRTO · Entity 6203	GrantStock Option (Right to Buy) · Derivative	12,700	$0.00 Strike: $2.50	$0.00	Disclosure SEC source: 0001171843-18-004579 · formfour.xml · derivative · entry 1 Canute Scott A · CIK 0001303416 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,700 Underlying: Common Stock · 12,700 shares Expires 2028-06-07 F1 · derivative.exercise_date: The options were granted on June 8, 2018 and the shares underlying this option will vest 100% at the earlier of (i) June 8, 2019 and (ii) the Issuer's next annual meeting of stockholders. Read SEC document
April 02, 2018 Filed Sep 18, 2018 14:59 UTC	IMMUNOMEDICS INC IMMU · Entity 145732	GrantStock Options (right to buy) · Derivative	6,497	$0.00 Strike: $14.29	$0.00	Disclosure SEC source: 0001171843-18-006604 · ownership.xml · derivative · entry 2 Canute Scott A · CIK 0001303416 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,497 Underlying: Common Stock, par value $0.01 per share · 6,497 shares Expires 2025-04-02 F1 · date: Such grants of restricted stock units and stock options were made automatically pursuant to the Issuer's compensation policy for non-employee directors as of the date of the Issuer's 2018 annual meeting of stockholders, which occurred on April 2, 2018. F3 · derivative.exercise_date: The stock options vest on the first anniversary of the date of grant, subject to the Reporting Person's continued service as a director of the Issuer. Read SEC document
April 02, 2018 Filed Sep 18, 2018 14:59 UTC	IMMUNOMEDICS INC IMMU · Entity 145732	GrantCommon Stock, $0.01 par value per share	3,849	$0.00	$0.00	Disclosure SEC source: 0001171843-18-006604 · ownership.xml · nonDerivative · entry 1 Canute Scott A · CIK 0001303416 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,849 F1 · date: Such grants of restricted stock units and stock options were made automatically pursuant to the Issuer's compensation policy for non-employee directors as of the date of the Issuer's 2018 annual meeting of stockholders, which occurred on April 2, 2018. F2 · shares: Includes restricted stock units that represent a contingent right to receive one share of the Issuer's common stock. The restricted stock units shall vest on the first anniversary of the date of grant, subject to the Reporting Person's continued service as a director of the Issuer. F2 · balance_after: Includes restricted stock units that represent a contingent right to receive one share of the Issuer's common stock. The restricted stock units shall vest on the first anniversary of the date of grant, subject to the Reporting Person's continued service as a director of the Issuer. Read SEC document
October 26, 2017 Filed Oct 30, 2017 18:02 UTC	Outlook Therapeutics, Inc. ONS · Entity 608	GrantStock Option (Right to Buy) · Derivative	15,000	$0.00 Strike: $1.32	$0.00	Disclosure SEC source: 0001209191-17-058361 · doc4.xml · derivative · entry 1 Canute Scott A · CIK 0001303416 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2027-10-26 F1 · derivative.exercise_date: 100% of the shares underlying the option shall vest on October 26, 2018, subject to the Reporting Person providing continuous service to the Issuer on such date. Read SEC document
July 03, 2017 Filed Jul 6, 2017 18:04 UTC	IMMUNOMEDICS INC IMMU · Entity 145732	GrantStock Options (right to buy) · Derivative	22,500	$0.00 Strike: $9.02	$0.00	Disclosure SEC source: 0001104659-17-043899 · a4.xml · derivative · entry 1 Canute Scott A · CIK 0001303416 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock, par value $0.01 per share · 22,500 shares Expires 2024-07-03 Read SEC document
June 22, 2017 Filed Jul 27, 2017 09:36 UTC	Flexion Therapeutics Inc FLXN · Entity 16545	GrantStock Option (Right to Buy) · Derivative	12,500	$0.00 Strike: $20.16	$0.00	Disclosure SEC source: 0001209191-17-046388 · doc4.xml · derivative · entry 1 Canute Scott A · CIK 0001303416 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2027-06-21 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 12 equal monthly installments following the date of grant. Read SEC document
June 20, 2017 Filed Jun 21, 2017 16:18 UTC	Protara Therapeutics, Inc. PRTO · Entity 6203	GrantStock Option (Right to Buy) · Derivative	6,666	$0.00 Strike: $1.30	$0.00	Disclosure SEC source: 0001171843-17-003746 · formfour.xml · derivative · entry 1 Canute Scott A · CIK 0001303416 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,666 Underlying: Common Stock, $0.001 par value · 6,666 shares Expires 2027-06-19 F1 · derivative.exercise_date: The options were granted on June 20, 2017 and the shares underlying this option will vest 100% at the earlier of (i) June 20, 2018 and (ii) the Issuer's next annual meeting of stockholders. Read SEC document
June 15, 2017 Filed Jun 19, 2017 16:05 UTC	Akebia Therapeutics, Inc. AKBA · Entity 6105	GrantStock Option (Right to buy) · Derivative	12,500	$0.00 Strike: $14.37	$0.00	Disclosure SEC source: 0001562180-17-002294 · primarydocument.xml · derivative · entry 1 Canute Scott A · CIK 0001303416 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2027-06-15 F1 · derivative.exercise_date: 100% of the option shares vest on the first anniversary of the date of grant (the "Vesting Date"), provided that the Reporting Person remains in continuous service as a member of the Issuer's Board of Directors through the Vesting Date, and provided further that the options held by the Reporting Person shall be eligible for vesting acceleration upon a "Change in Control" as defined and provided for in the Issuer's Non-Employee Director Stock Option Award Agreement. Read SEC document
December 22, 2016 Filed Dec 27, 2016 16:54 UTC	Outlook Therapeutics, Inc. ONS · Entity 608	PurchaseWarrant (Right to Buy) · Derivative	80,500	$0.00 Strike: $3.00	$0.00	Disclosure SEC source: 0001209191-16-156824 · doc4.xml · derivative · entry 1 Canute Scott A · CIK 0001303416 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,500 Underlying: Common Stock · 80,500 shares Expires 2021-12-22 F2 · price: The Reporting Person acquired a Senior Secured Note in the principal amount of $350,000 together with a Warrant to purchase 80,500 shares of the common stock of the Issuer in exchange for the Reporting Person's Unsecured Bridge Note in the principal amount of $350,000. F1 · derivative.exercise_date: Immediately exercisable. Read SEC document
November 28, 2016 Filed Nov 30, 2016 17:22 UTC	Outlook Therapeutics, Inc. ONS · Entity 608	OtherWarrant (Right to Buy) · Derivative	37,315	$0.00 Strike: $0.01	$0.00	Disclosure SEC source: 0001209191-16-152512 · doc4.xml · derivative · entry 2 Canute Scott A · CIK 0001303416 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,315 Underlying: Common Stock · 37,315 shares Expires 2019-11-08 F1 · kind: Pro rata distribution from Proximare Lifesciences Fund LLC, of which the reporting person is a member. F1 · shares: Pro rata distribution from Proximare Lifesciences Fund LLC, of which the reporting person is a member. F2 · derivative.exercise_date: Immediately exercisable. F1 · derivative.underlying_shares: Pro rata distribution from Proximare Lifesciences Fund LLC, of which the reporting person is a member. F1 · balance_after: Pro rata distribution from Proximare Lifesciences Fund LLC, of which the reporting person is a member. Read SEC document
November 28, 2016 Filed Nov 30, 2016 17:22 UTC	Outlook Therapeutics, Inc. ONS · Entity 608	OtherCommon Stock	57,408	$0.00	$0.00	Disclosure SEC source: 0001209191-16-152512 · doc4.xml · nonDerivative · entry 1 Canute Scott A · CIK 0001303416 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 246,342 F1 · kind: Pro rata distribution from Proximare Lifesciences Fund LLC, of which the reporting person is a member. F1 · shares: Pro rata distribution from Proximare Lifesciences Fund LLC, of which the reporting person is a member. F1 · price: Pro rata distribution from Proximare Lifesciences Fund LLC, of which the reporting person is a member. Read SEC document
November 09, 2016 Filed Nov 14, 2016 18:18 UTC	Outlook Therapeutics, Inc. ONS · Entity 608	Exercise / conversionCommon Stock	57,971	Not disclosed	Not disclosed	Disclosure SEC source: 0001214659-16-014638 · marketforms-36752.xml · nonDerivative · entry 2 Canute Scott A · CIK 0001303416 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 188,934 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each restricted stock unit ("RSU") represents the right to receive, at settlement, one (1) share of the Issuer's common stock. Read SEC document
November 09, 2016 Filed Nov 14, 2016 18:18 UTC	Outlook Therapeutics, Inc. ONS · Entity 608	ConversionRestricted Stock Units	57,971	$0.00	$0.00	Disclosure SEC source: 0001214659-16-014638 · marketforms-36752.xml · nonDerivative · entry 1 Canute Scott A · CIK 0001303416 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Granted pursuant to the Issuer's 2015 Equity Incentive Plan. F2 · shares: Each restricted stock unit ("RSU") represents the right to receive, at settlement, one (1) share of the Issuer's common stock. F3 · shares: The RSUs vest upon the first to occur of (x) a change of control as defined in the award agreement and (y) the expiration of the 6 month lock-up period following the Issuer's initial public offering ("IPO"), in each case subject to continued service through such event. Read SEC document
February 01, 2007 Filed Feb 5, 2007 23:23 UTC	ELI LILLY & Co LLY · Entity 2794	Tax withholdingCommon Stock	3,668	$54.12	$198,512.16	Disclosure SEC source: 0001209191-07-007667 · doc4.xml · nonDerivative · entry 1 Canute Scott A · CIK 0001303416 · President, Mfg. Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,367 Read SEC document
January 17, 2007 Filed Jan 19, 2007 20:33 UTC	ELI LILLY & Co LLY · Entity 2794	GrantCommon Stock	17,355	$52.86	$917,385.30	Disclosure SEC source: 0001209191-07-004338 · doc4.xml · nonDerivative · entry 1 Canute Scott A · CIK 0001303416 · President, Mfg. Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,035 Read SEC document
June 13, 2006 Filed Feb 12, 2007 20:06 UTC	ELI LILLY & Co LLY · Entity 2794	GiftCommon Stock	1,293	$0.00	$0.00	Disclosure SEC source: 0001209191-07-009372 · doc5.xml · nonDerivative · entry 1 Canute Scott A · CIK 0001303416 · President, Mfg. Operations 10b5-1 filing: Not disclosed Ownership: Indirect · Amy D. Canute Rev. Trust Disclosed balance after: 18,078 F1 · ownership.direct: Revocable Trust of which reporting person and his wife are trustee. Read SEC document
February 10, 2006 Filed Feb 14, 2006 22:02 UTC	ELI LILLY & Co LLY · Entity 2794	GrantEmployee stock option 2/06 (right to buy) · Derivative	39,157	$0.00 Strike: $56.18	$0.00	Disclosure SEC source: 0001209191-06-010481 · doc4.xml · derivative · entry 1 Canute Scott A · CIK 0001303416 · President, Mfg. Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,157 Underlying: Common Stock · 39,157 shares Expires 2016-02-09 Read SEC document
January 20, 2006 Filed Jan 24, 2006 20:00 UTC	ELI LILLY & Co LLY · Entity 2794	GrantCommon Stock	11,680	$57.04	$666,227.20	Disclosure SEC source: 0001209191-06-004693 · doc4.xml · nonDerivative · entry 1 Canute Scott A · CIK 0001303416 · President, Mfg. Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,680 Read SEC document
August 29, 2005 Filed Feb 14, 2006 17:07 UTC	ELI LILLY & Co LLY · Entity 2794	GiftCommon Stock	6,000	$0.00	$0.00	Disclosure SEC source: 0001209191-06-010178 · doc5.xml · nonDerivative · entry 8 Canute Scott A · CIK 0001303416 · President, Mfg. Operations 10b5-1 filing: Not disclosed Ownership: Indirect · Amy D. Canute Rev. Trust Disclosed balance after: 19,371 F1 · ownership.direct: Revocable Trust of which reporting person and his wife are trustee. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.